Document Detail


Preventive effects of transdermal 17 beta-estradiol on osteoporotic changes after surgical menopause: a two-year placebo-controlled trial.
MedLine Citation:
PMID:  8420311     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: The purpose of our study was to evaluate the effects of three dosages of transdermally administered 17 beta-estradiol on markers of bone loss in women who had recently undergone surgical menopause. STUDY DESIGN: This was a 2-year, randomized, double-blind, placebo-controlled study that reviewed 127 women stratified by age. Biochemical indicators of bone metabolism in urine and serum were periodically assessed, as was bone mineral content of the lumbar spine and radius. Statistical analysis examined the percent changes from baseline in bone mineral density by using an analysis of covariance with treatment as a factor and the baseline value as a covariant, by performing all-pairwise comparisons among the three estradiol groups, and by testing for a linear dose-response relationship. RESULTS: After 2 years of therapy, a significant dose-response relationship was detected. CONCLUSION: This 2-year study demonstrates that transdermally administered 17 beta-estradiol is a safe and effective regimen for preventing bone loss in recently postmenopausal women.
Authors:
C S Field; S J Ory; H W Wahner; R R Herrmann; H L Judd; B L Riggs
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  American journal of obstetrics and gynecology     Volume:  168     ISSN:  0002-9378     ISO Abbreviation:  Am. J. Obstet. Gynecol.     Publication Date:  1993 Jan 
Date Detail:
Created Date:  1993-02-11     Completed Date:  1993-02-11     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0370476     Medline TA:  Am J Obstet Gynecol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  114-21     Citation Subset:  AIM; IM    
Affiliation:
Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN 55905.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Bone Density / drug effects*
Calcium / urine
Cholesterol / blood
Dose-Response Relationship, Drug
Double-Blind Method
Estradiol / administration & dosage*
Estrogen Replacement Therapy*
Female
Humans
Hydroxyproline / urine
Hysterectomy / adverse effects*
Injections, Intradermal
Middle Aged
Osteoporosis, Postmenopausal / blood,  prevention & control*,  urine
Chemical
Reg. No./Substance:
50-28-2/Estradiol; 51-35-4/Hydroxyproline; 57-88-5/Cholesterol; 7440-70-2/Calcium

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  First-trimester ultrasonography findings in women with a history of recurrent pregnancy loss.
Next Document:  The reliability of ultrasonography in the management of spontaneous abortion, clinically thought to ...